CEO Clips - Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial
Stocks to Invest in: Healthcare
Focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and chronic kidney disease
Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
The company was recently granted permission to conduct a Phase 1 clinical study of an intravenous formulation of AP-188 or DMT for the treatment of stroke.
CEO & Director - Christopher J. Moreau
Mr. Moreau is the CEO of Algernon Pharmaceuticals Inc. and a member of the company’s board of directors. With over 30 years of executive management experience, including 15 years in CEO roles, he has proven achievements in operations management, acquisitions, licensing, and integration. Mr. Moreau also has significant experience managing biotechnology research programs, and a deep expertise in business development and capital markets, having raised more than $50 million. He has also been featured on numerous business television and social media interviews, and is a highly skilled communicator and sought-after speaker, recently appearing as a guest Lecturer for the University of East London, Pharmacology program.
For more information on Algernon Pharmaceuticals (CSE: AGN, OTCQB: AGNPF) please click the request investor info button.